Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34NSCLC 9Meningeal Carcinomatosis 5Adenocarcinoma of Lung 5Lung Neoplasms 4Brain Neoplasms 4Respiratory Tract Neoplasms 1Pleural Effusion, Malignant 1Non Small Cell Lung Cancer NSCLC 1Neoplasm, Residual 1Multiple Primary Lung Cancers 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1Advanced Non-small Cell Lung Cancer 1Advanced NSCLC Patients With T790M 1Advanced NSCLC 1Advanced Lung Cancer 1Adenocarcinoma 1

Interventions

aflutinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer × aflutinib × Clear all
NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)

Allist Pharmaceuticals, Inc.

Phase 3 Active not recruiting
358 enrolled
Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡